{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:27:37Z","timestamp":1783024057697,"version":"3.54.6"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    A patient with metastatic atypical right lung carcinoid underwent\n                    <jats:sup>68<\/jats:sup>\n                    Ga-FAP2286 and\n                    <jats:sup>68<\/jats:sup>\n                    Ga-DOTATATE PET\/CT scans to assess eligibility for radionuclide therapy, which revealed insufficient coverage of all lesions by either tracer. The imaging also identified a prostate mass with markedly elevated PSA level; biopsy confirmed prostate adenocarcinoma with neuroendocrine differentiation. Subsequent\n                    <jats:sup>68<\/jats:sup>\n                    Ga-PSMA PET\/CT demonstrated high uptake in all lesions. Guided by these multimodal imaging, the patient received combined\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA and\n                    <jats:sup>177<\/jats:sup>\n                    Lu-DOTA-IBA therapy. Notably, he achieved near-complete remission of both primary malignancies and all metastases after one cycle of cocktail therapy and one cycle of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-DOTA-IBA therapy.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006380","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:00:14Z","timestamp":1771261214000},"page":"664-666","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Remarkable Response to 177Lu-PSMA and 177Lu-DOTA-IBA Cocktail Therapy in a Patient With Dual Primary Malignancies"],"prefix":"10.1097","volume":"51","author":[{"given":"Chunmei","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Bo","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Urology, Sichuan Clinical Research Center for Nephropathy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00259-021-05296-1","article-title":"Prospective comparison of (18)F-PSMA-1007 PET\/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer","volume":"48","author":"Malaspina","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R2-20260702","first-page":"255","article-title":"Radiotheranostics in oncology: making precision medicine possible","volume":"73","author":"Aboagye","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1021\/acs.molpharmaceut.2c00978","article-title":"Lutetium177-labeled DOTA-ibandronate: a novel radiopharmaceutical for targeted treatment of bone metastases","volume":"20","author":"Wang","year":"2023","journal-title":"Mol Pharm"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/RLU.0000000000004634","article-title":"Safety and Efficacy of 68 Ga- or 177 Lu-Labeled DOTA-IBA as a novel theranostic radiopharmaceutical for bone metastases: a phase 0\/I study","volume":"48","author":"Qiu","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/RLU.0000000000005573","article-title":"Efficacy and safety of 177Lu-DOTA-IBA in tumor bone metastasis treatment: a prospective clinical trial","volume":"50","author":"Xu","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R7-20260702","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/RLU.0000000000005303","article-title":"Flare phenomenon after 177 Lu-DOTA-IBA therapy in bone metastases of lung cancer","volume":"49","author":"Hua","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"Suppl 1","key":"R8-20260702","first-page":"13s","article-title":"Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs","volume":"46","author":"de Jong","year":"2005","journal-title":"J Nucl Med"},{"key":"R9-20260702","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1200\/JCO.2011.37.2151","article-title":"Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers","volume":"30","author":"Villard","year":"2012","journal-title":"J Clin Oncol"},{"key":"R10-20260702","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2967\/jnumed.123.267206","article-title":"Deescalated (225)Ac-PSMA-617 versus (177)Lu\/(225)Ac-PSMA-617 cocktail therapy: a single-center retrospective analysis of 233 patients","volume":"65","author":"Rathke","year":"2024","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:10:26Z","timestamp":1783023026000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006380","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"2025-12-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}